ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. The company's clinical stage candidates include QR-010, a RNA-based oligonucleotide that is in Phase Ib clinical trial for the treatment of cystic fibrosis. It also develops QR-110, which is in pre-clinical development stage for the treatment of Leber's congenital amaurosis. The company was founded in 2012 and is headquartered in Leiden, the Netherlands.
http://www.priceseries.com/trade/PRQR-ProQR-Therapeutics-NV-stock-gains-32-percent-a-Trade-Record-by-priceSeries-2018050320180530.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments